Who
Joseph Talamo
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Intensity Therapeutics; SVP and CFO, Lisata Therapeutics.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 29 Jun 2011
- Last trade
- 16 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $3,8091,093 at $3.49 | filing |
| 30 Jun 2026filed 1 Jul 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $3,8151,093 at $3.49 | filing |
| 31 Dec 2025filed 5 Jan 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $3,79414,482 at $0.262 | filing |
| 31 Dec 2025filed 5 Jan 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $3,76514,482 at $0.26 | filing |
| 30 Jun 2025filed 2 Jul 2025 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $3,68714,179 at $0.26 | filing |
| 2 May 2025filed 6 May 2025 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 21 Oct 2024filed 23 Oct 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —427,379 at $0.00 | filing |
| 11 Dec 2023filed 12 Dec 2023 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 14 Jan 2020filed 15 Jan 2020 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,4022,190 at $3.38 | filing |
| 13 Jan 2020filed 15 Jan 2020 | LSTA Lisata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,000 at $0.00 | filing |
| 13 Jan 2020filed 15 Jan 2020 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 13 Jan 2020filed 15 Jan 2020 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,5312,601 at $3.28 | filing |
| 8 Jan 2020filed 9 Jan 2020 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,1531,821 at $2.83 | filing |
| 14 Jan 2019filed 16 Jan 2019 | LSTA Lisata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 14 Jan 2019filed 16 Jan 2019 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 14 Jan 2019filed 16 Jan 2019 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | —2,159 at $0.00 | filing |
| 8 Jan 2019filed 10 Jan 2019 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,3291,795 at $4.64 | filing |
| 20 Jun 2018filed 21 Jun 2018 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | $115K13,300 at $8.64 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.